Ardelyx (ARDX) Other Non-Current Liabilities (2013 - 2026)
Ardelyx (ARDX) reported Other Non-Current Liabilities of $25.9 million for Q1 2026, down 2.48% on a YoY basis from $26.5 million in Q1 2025, and little changed quarter-over-quarter from $25.9 million in Q4 2025.
Ardelyx (ARDX) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Ardelyx has reported Other Non-Current Liabilities for 13 years, with the latest figure at $25.9 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 2.48% year-over-year to $25.9 million; the trailing twelve-month figure through Mar 2026 stood at $25.9 million (down 2.48% YoY), and the FY2025 full-year result was $25.9 million, up 1.37% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $25.9 million, roughly flat from $25.9 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $28.6 million in Q3 2025, with the low at $172000.0 in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $19.2 million across 5 years, with a median of $22.5 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities slumped 98.21% — and 2024, when it soared 13332.56%.
- Ardelyx's Other Non-Current Liabilities stood at $11.3 million in 2022, then surged by 79.31% to $20.2 million in 2023, then increased by 26.5% to $25.5 million in 2024, then increased by 1.37% to $25.9 million in 2025, then declined by 0.05% to $25.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $25.9 million (Q1 2026), $25.9 million (Q4 2025), and $28.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.86 Mn |
| Dec 31, 2025 | 25.88 Mn |
| Sep 30, 2025 | 28.63 Mn |
| Jun 30, 2025 | 27.76 Mn |
| Mar 31, 2025 | 26.52 Mn |
| Dec 31, 2024 | 25.53 Mn |
| Sep 30, 2024 | 24.37 Mn |
| Jun 30, 2024 | 23.10 Mn |
| Mar 31, 2024 | 21.88 Mn |
| Dec 31, 2023 | 20.18 Mn |
| Sep 30, 2023 | 14.11 Mn |
| Jun 30, 2023 | 172,000.00 |
| Mar 31, 2023 | 12.22 Mn |
| Dec 31, 2022 | 11.25 Mn |
| Sep 30, 2022 | 10.42 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Dec 31, 2020 | 1.38 Mn |
| Sep 30, 2020 | 1.26 Mn |
| Jun 30, 2020 | 1.12 Mn |
| Mar 31, 2020 | 1.05 Mn |